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Signaling Leads to Hypercholesterolemia 
and Promotes Hepatic Steatosis and 
Insulin Resistance
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Adenosine monophosphate–activated protein kinase (AMPK) regulates multiple signaling pathways involved in glu-
cose and lipid metabolism in response to changes in hormonal and nutrient status. Cell culture studies have shown 
that AMPK phosphorylation and inhibition of the rate-limiting enzyme in the mevalonate pathway 3-hydroxy-
3-methylglutaryl (HMG) coenzyme A (CoA) reductase (HMGCR) at serine-871 (Ser871; human HMGCR Ser872) 
suppresses cholesterol synthesis. In order to evaluate the role of AMPK-HMGCR signaling in vivo, we generated 
mice with a Ser871-alanine (Ala) knock-in mutation (HMGCR KI). Cholesterol synthesis was significantly sup-
pressed in wild-type (WT) but not in HMGCR KI hepatocytes in response to AMPK activators. Liver cholesterol 
synthesis and cholesterol levels were significantly up-regulated in HMGCR KI mice. When fed a high-carbohydrate 
diet, HMGCR KI mice had enhanced triglyceride synthesis and liver steatosis, resulting in impaired glucose homeo-
stasis. Conclusion: AMPK-HMGCR signaling alone is sufficient to regulate both cholesterol and triglyceride synthe-
sis under conditions of a high-carbohydrate diet. Our findings highlight the tight coupling between the mevalonate 
and fatty acid synthesis pathways as well as revealing a role of AMPK in suppressing the deleterious effects of a 
high-carbohydrate diet. (Hepatology Communications 2019;3:84-98).
The mevalonate pathway is essential for the synthesis of important nonsterol isoprenoids and bioactive sterols, such as cholesterol, 
that are involved in multiple aspects of cellular 
metabolism. It is also an essential precursor of bile 
acid, lipoproteins, steroid hormones, and vitamin 
D. 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase (HMGCR) is a ubiquitously expressed endo-
plasmic reticulum-localized enzyme that functions 
to convert 3-hydroxy-3-methylglutaryl coenzyme A 
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(HMG-CoA) to mevalonate and is the rate-limit-
ing enzyme of the mevalonate pathway. Early stud-
ies demonstrated that genetic deletion of HMGCR 
in mice results in early embryonic lethality (between 
embryonic day 3 Similarly, recent studies have shown 
that liver-specific HMGCR-deficient mice develop 
severe liver function failure and die before 6 weeks, 
indicating that the mevalonate pathway is indispens-
able for development and essential for the survival of 
mice.(2)
HMGCR is subject to regulation at multiple levels 
that involve feedback control and cross-regulation by 
distinct biochemical pathways.(3,4) For instance, abun-
dant sterols suppress hmgcr gene transcription,(5) and 
sterols and nonsterols derived from the mevalonate 
pathway synergistically suppress HMGCR protein 
synthesis by translational regulation.(6) HMGCR is 
also exquisitely regulated at the level of protein stabil-
ity, where HMGCR degradation is accelerated in cells 
in the presence of sterols or mevalonate.(7-9)
Early in vitro studies demonstrated that 
HMGCR activity can also be regulated by adenosine 
monophosphate–activated protein kinase (AMPK).(10) 
In fact, regulation of HMGCR by reversible phos-
phorylation was reported by multiple laboratories in 
the 1970s,(11,12) but at that time the identity of the 
associated reductase-inactivating kinase was not 
known; it was not until 1987 that the term AMPK 
was adopted.(13) AMPK is a key regulator of whole-
body energy metabolism, including lipid metabolism, 
protein synthesis, glucose uptake, and mitochondrial 
biogenesis.(10,14) AMPK is present in all tissues as a het-
erotrimeric complex composed of a catalytic α subunit 
(α1, α2), a scaffolding β subunit (β1, β2), and a nucleo-
tide-binding γ subunit (γ1, γ2, γ3) and is typically inac-
tive unless phosphorylated on threonine-172 (Thr172) 
in the α subunit activation loop by upstream kinases 
(liver kinase B1, calcium/calmodulin-dependent pro-
tein kinase kinase-2 [CaMKK2]).(10,14) AMPK is acti-
vated by metabolic stresses(15-17) or hormonal changes 
that signal low-energy conditions (muscle contraction, 
ischemia, starvation) and acts to inhibit anabolic ade-
nosine triphosphate (ATP)-consuming pathways and 
promote catabolic ATP-generating pathways.(10)
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AMPK was shown to inactivate HMGCR by 
phosphorylating serine-871 (Ser871) in vitro(18) and 
in cell lines(19); however, both wild-type (WT) and 
Ser871 alanine (Ala) HMGCR mutants were equally 
sensitive to end-product feedback control, making it 
unclear how important AMPK-HMGCR signaling is 
in the context of the whole animal beyond conditions 
of severe metabolic stress. To determine the phys-
iologic importance of Ser871 phosphorylation, we 
generated HMGCR Ser871Ala knock-in (KI) mice 
by homologous recombination. We show that inhi-
bition of Ser871 phosphorylation leads to increased 
cholesterol synthesis and cholesterol accumulation 
in the liver and, surprisingly, an elevated capacity 
for triglyceride synthesis. Furthermore, Ser871Ala 
HMGCR mutant mice fed a high-carbohydrate diet 
develop hepatic steatosis and show reduced insulin 
sensitivity with reduced insulin-induced suppression 
of hepatic glucose output.
Materials and Methods
animals
All animal care and experiments were approved 
by St. Vincent’s Hospital (Melbourne, Australia) 
Animal Ethics Committee and the University of 
Ottawa Animal Care Committee (Ottawa, Canada) 
and were carried out in accordance with the 
approved guidelines. HMGCR KI mice were gener-
ated and genotyped as described in the Supporting 
Experimental Procedures. Male mice on a C57BL/6 
background were used for all experiments. Mice were 
housed under a controlled temperature of 22°C and 
a 12-hour light cycle (lights on from 7 am to 7 pm) 
with ad libitum access to water and a standard chow 
diet (6% fat, 29% starch; #102108, Barastoc; Ridley 
Agriproducts) or fed a high-carbohydrate diet (7% 
fat, 60% dextrose; #SF03-023; Specialty Feeds, Glen 
Forrest, Australia) for 10 weeks starting from 8 to 10 
weeks of age.
IN VIVO HepatiC CHolesteRol 
syntHesis
For in vivo cholesterol and triglyceride synthe-
sis assays, liver was isolated from mice 1 hour after 
intraperitoneal injection with 10 mCi of [3H] H2O 
(Perkin Elmer) in 0.2 mL of phosphate-buffered 
saline (PBS). In parallel, trunk blood was also col-
lected, and the [3H] H2O activity in the plasma 
was measured. For triglyceride detection, the lipid 
fraction was extracted by homogenizing the liver in 
chloroform:methanol (2:1). Lipids were separated by 
thin-layer chromatography (TLC) (hexane:diethyl 
ether:glacial acetic acid, 80:20:1). For cholesterol 
measurements, the liver was saponified before lipid 
extraction and TLC. The tracer incorporated into 
the triglyceride or cholesterol fraction was measured 
by liquid scintillation counting, and synthesis rates 
were calculated as nmol of 3H-labeled water incor-
porated into cholesterol per milligram of protein per 
hour as described.(20)
EX VIVO lipogenesis assay
Primary hepatocytes were isolated by collagenase per-
fusion.(21) Lipogenesis was determined by measuring the 
incorporation of [3H]acetate as described.(22) Briefly, cells 
were cultured for 2 hours in serum-free M199 before 
pretreatment for 1 hour with 10 μM A769662 or 0.5 
mM 5-aminoimidazole-4-carboxamide ribonucleotide 
(AICAR), followed by incubation with [3H]acetate (5 
μCi/mL) and 0.5 mM sodium acetate for 4 hours in the 
continued presence of A769662 or AICAR. Medium 
was then removed and cells washed with PBS before 
lipid extraction for determination of incorporation into 
lipid fractions as described above.
WesteRn Blotting
Mouse tissues (liver and muscle) were dissected 
and immediately frozen in liquid nitrogen. Tissues 
were mechanically homogenized in ice-cold radio 
immunoprecipitation assay lysis buffer, and protein 
was resolved by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis and immunoblotted with 
antibodies against phosphorylated Ser473-protein 
kinase B (Akt; #4058), Akt (#9272), phosphorylated 
Thr172 AMPK (#2535), AMPK pan-α (#5831), and 
pan-actin (#4968) (all antibodies from Cell Signaling 
Technologies) and HMGCR antibody (#ABS229; 
Merck Millipore). Proteins were detected using the 
enhanced chemiluminescence method after incuba-
tion with horseradish peroxidase-conjugated rabbit 
antibodies (Dako) as described.(22) Immunolabeled 
bands were quantified by densitometry using ImageJ 
software.




Tissues were dissected and immediately frozen in liq-
uid nitrogen. RNA was extracted using Trizol Reagent 
(Sigma) and isolated according to the manufacturer’s 
instructions. Complementary DNA was generated using 
the Thermoscript real-time polymerase chain reaction 
(RT-PCR) system (Life Technologies) and analyzed by 
means of quantitative RT-PCR on a Rotorgene 3000 
(Corbett Research) using Assay-on-Demand gene 
expression assays (Life Technologies) according to the 
manufacturer’s recommendations. Assays were normal-
ized using 18S ribosomal RNA or ribosomal protein 
L32, and expression levels were calculated using the 
comparative critical threshold method as described.(22) 
A list of the TaqMan Gene Expression Assays used in 
this study is shown in Supporting Table S2.
musCle gluCose uptaKe assay
Muscle 2-deoxy-D-glucose uptake was measured as 
described.(23) Briefly, extensor digitorum longus (EDL) 
and soleus muscles were isolated from anesthetized 
mice and transferred into flasks containing essential 
buffer (Krebs-Henseleit buffer, pH 7.4, supplemented 
with 2 mM pyruvate, 8 mM mannitol, and 0.1% 
bovine serum albumin), gassed with 95% O2/5% O2 at 
30°C for 10 minutes, followed by incubation in essen-
tial buffer containing 400 μU/mL insulin (Actrapid, 
Novo Nordisk). 2-deoxy-D-glucose uptake was mea-
sured over the following 20 minutes in a similar buffer 
supplemented with 0.5 μCi/mL of 2-[2,6H3] deoxy-
D-glucose, 0.2 μCi/mL [1-14C] mannitol, and 1 mM 
2-deoxy-D-glucose. Muscles were removed, washed 
with PBS, and homogenized in cell lysis buffer as 
described.(23) The homogenate was clarified by cen-
trifugation, and radioactivity of the supernatant was 
determined by liquid scintillation counting.
HypeRinsulinemiC-
euglyCemiC Clamp
Hyperinsulinemic-euglycemic clamps were per-
formed as described.(24) Briefly, a catheter was sur-
gically placed into the right jugular vein, and mice 
were allowed to recover for 5 days. All mice regained 
their presurgical weights following surgery. The cath-
eter was made accessible through an adaptor port 
implanted on the dorsal subscapular region. On the 
day of the clamp, mice were fasted for 5 hours and 
then infused with D-[3-3H]-glucose for 1 hour to 
evaluate basal glucose disposal. A human insulin 
(10 mU/kg/minute) infusate containing D-[3-3H]-
glucose was then infused, and blood glucose levels 
were titrated with 50% dextrose to achieve and main-
tain euglycemia. Mice were not physically restrained 
but free to move around the top of the cage. Basal and 
clamped rates of glucose disposal and hepatic glucose 
production (HGP) were calculated as stated.(24) All 
tissues were rapidly dissected, snap frozen in liquid 
nitrogen, and stored at −80°C for later analyses.
oil ReD o anD liVeR 
Histology
Frozen livers sections (6 µm) were cut on a cryostat, 
mounted on slides, fixed for 30 minutes in 4% parafor-
maldehyde, and processed for Oil Red O staining as 
described.(25) To quantify lipid infiltration in the liver, 
Oil Red O-stained sections were assessed on a gray 
scale for stained pixels within a defined frame using 
a light microscope (Leica, Heerbrugg, Switzerland) at 
magnification ×200 and quantified using ImageJ soft-
ware. For liver histology, livers were collected, fixed 
in 10% formalin, and processed for hematoxylin and 
eosin, trichome collagen staining, and F4/80 macro-
phage immunohistochemistry as described.(26)
metaBoliC measuRements 
anD seRum assays
Weekly body weight was determined from 8 weeks 
of age onward unless otherwise stated. Food intake 
was examined in chow- and high-carbohydrate-fed 
mice as described.(25) Mice were killed by cervical 
dislocation, and tissues, including liver and white adi-
pose tissue, were weighed and stored for subsequent 
assays. Trunk blood was collected and centrifuged, 
and serum was obtained for further analysis. Hepatic 
and serum cholesterol (total, free, and cholesteryl 
ester; Abcam), serum very low-density lipoprotein/
low-density lipoprotein (VLDL/LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol (Abcam), 
serum nonesterified fatty acid (NEFA), and serum 
triglyceride (Wako Diagnostics) were measured with 
commercially available colorimetric kits in accordance 
with the manufacturers’ specifications.
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gluCose anD insulin 
toleRanCe tests
Fed and fasted blood glucose levels were measured 
using an Accu-Chek Go glucometer. Glucose and 
insulin tolerance tests were performed on 6-hour-
fasted or 4-hour-fasted mice that were adminis-
tered intraperitoneally with glucose (1 mg/g body 
weight) or insulin (0.5 mU/g body weight), respec-
tively. Blood glucose levels were assessed at 0, 15, 
30, 60, and 90 minutes after glucose administra-
tion using an Accu-Chek Go glucometer (Roche) as 
described.(27)
statistiCal analyses
All data are expressed as means ± SEM. A 2-tailed 
Student t test was used to test differences between two 
groups of mice. Differences among groups of mice 
were assessed by 2-way analysis of variance (ANOVA) 
or repeated-measures ANOVA. Bonferroni post hoc 
test was performed to identify differences among 
means. Statistical analyses were assessed using Prism 
software (GraphPad Software, Inc., La Jolla, CA).
Results
geneRation oF HmgCR 
seR871ala Ki miCe
The generation of HMGCR Ser871Ala KI mice is 
described in the Supporting Methods, and a schematic 
of the targeting construct is shown in Supporting Fig. 
S1. WT and HMGCR KI mice were genotyped using 
a PCR-based approach. The recombinant product 
(886 base pairs [bps]) was only detected in genomic 
DNA samples isolated from HMGCR KI mice 
(Fig. 1A). To confirm that the Ser871Ala KI muta-
tion in HMGCR blocks phosphorylation by AMPK 
and consequently renders it insensitive to inhibi-
tion by AMPK, WT and Ser871Ala KI glutathione 
S-transferase (GST)-tobacco etch virus protease site 
(TEV)-HMGCR (485-887) proteins were incubated 
in the presence of Mg2+/ATP for 10 minutes, with 
Fig. 1. The Ser871Ala mutation renders HMGCR insensitive to AMPK phosphorylation and inhibition. (A) Genotyping using 
PCR for determining WT, HET, and homozygous HMGCR KI mice. (B,C) The catalytic domains of WT and Ser871Ala KI mouse 
HMGCR were expressed as GST-fusion proteins and incubated with or without bacterial-expressed CaMKK-activated AMPK before 
(B) mass spectrometry analysis or (C) assay for HMGCR activity using a radioisotope-based 14C-HMG CoA reduction assay. Results 
are means ± SEM, n = 3 per group (*P < 0.05, when comparing no AMPK versus +AMPK). (D) Relative Hmgcs1 and Hmgcr mRNA 
expression determined in the liver by quantitative RT-PCR using Rpl32 as a housekeeping gene. Results are means ± SEM, n = 12 WT, 
n = 11 HMGCR KI. (E) Liver from WT and HMGCR KI mice were subjected to immunoblotting using antibodies against HMGCR 
and actin and quantified using ImageJ software. Results are means ± SEM, n = 3 per genotype. Abbreviations: HET, heterozygous; 
Rpl32, ribosomal protein L32.
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or without CaMKK2-activated bacterially expressed 
AMPK. The phosphorylation status was then mea-
sured by means of time-of-flight–mass spectrom-
etry analysis (Fig. 1B). Incubation with bacterially 
expressed AMPK in the presence of ATP resulted in 
an observed mass of 74,547 Da (theoretical mass of 
WT protein 74,465 Da), indicating a stoichiometric 
shift in the mass peak of 80 Da, equivalent to the 
mass of a phosphate group. More importantly, this 
shift was not observed in the Ser871Ala KI GST-
TEV-HMGCR (485-887)-EEF proteins (Fig. 1B). 
We next assessed HMGCR catalytic activity and 
validated whether the lack of phosphorylation by 
AMPK results in its inability to suppress HMGCR 
activity. Consistently, coincubation with AMPK did 
not inhibit the reductase activity of Ser871Ala KI 
GST-TEV-HMGCR (485-887)-EEF (Fig. 1C), 
whereas the activity of the WT enzyme was signifi-
cantly reduced by approximately 75%. Taken together, 
these results show that the HMGCR Ser871Ala KI 
mutation rendered the enzyme insensitive to phos-
phorylation and inhibition by AMPK and confirm 
that Ser871 is the sole AMPK phosphorylation site 
in the HMGCR catalytic domain.
HMGCR KI mice were viable and displayed no 
visible developmental defects. Breeding of female het-
erozygous (HET) HMGCR KI mice with male HET 
HMGCR KI mice or vice versa resulted in live off-
spring with a genotype frequency not different from 
the expected Mendelian ratio (Supporting Table S1); 
nor was there a significant difference between WT 
and HMGCR KI mice in terms of litter size, litter 
intervals, or sex ratio of pups (Supporting Table S1), 
indicating that the Ser871Ala mutation in HMGCR 
does not impact reproductive fitness. Moreover, the 
HMGCR Ser871Ala point mutation in mice did not 
lead to any significant changes in the hepatic mes-
senger RNA (mRNA) expression of HMG-CoA 
synthase-1 (Hmgcs1) and Hmgcr (Fig. 1D) or protein 
levels of HMGCR (Fig. 1E).
ReDuCeD CHolesteRol-
loWeRing eFFeCts oF 
ampK aCtiVation in HmgCR 
seR871ala Ki HepatoCytes
To determine the physiologic significance of 
HMGCR regulation by AMPK in cholesterol metab-
olism, we first determined the capacity for cholesterol 
synthesis in primary hepatocytes isolated from WT 
and HMGCR KI mice. We found that basal rates of 
synthesis were not different between the genotypes; 
however, HMGCR KI hepatocytes compared to WT 
hepatocytes had reduced sensitivity to the cholester-
ol-lowering effects of the AMPK activators A769662 
and AICAR (Fig. 2A).
We subsequently measured a number of metabolic 
parameters in WT and HMGCR KI mice and found 
there were no differences in body weight, liver weight, 
and adiposity when mice were fed a standard chow 
diet (Supporting Fig. S2A-C). Consistent with similar 
cholesterol synthesis under basal conditions in primary 
hepatocytes, liver cholesterol content was also not dif-
ferent between WT and HMGCR KI mice; however, 
serum total cholesterol levels were modestly elevated 
in HMGCR KI mice (Fig. 2B,C). Overall, these 
results indicate that the absence of AMPK-HMGCR 
signaling does not lead to overt perturbations of cho-
lesterol metabolism under chow-fed conditions.
enHanCeD CHolesteRol 
syntHesis in HmgCR 
seR871ala Ki miCe FeD a HigH-
CaRBoHyDRate Diet
The lack of a phenotype in HMGCR KI mice in 
the basal conditions may reflect that Ser871 phosphor-
ylation is either redundant for controlling HMGCR 
activity or is sufficiently important that its function 
is backed up by other mechanisms, such as regulation 
at the translational and transcriptional level. To test 
whether the effect of the HMGCR Ser871Ala muta-
tion may be more evident under a condition where 
the mevalonate pathway is activated, we fed WT and 
HMGCR KI mice a lipogenic high-carbohydrate diet 
(60% dextrose) for 10 weeks. The primary purpose 
of feeding mice a lipogenic high-carbohydrate diet is 
to increase the flux through lipid synthesis, including 
cholesterol synthesis in the liver, by increasing the sup-
ply of the precursor acetyl-CoA in these pathways. We 
confirmed that high-carbohydrate feeding increased 
rates of hepatic triglyceride and cholesterol synthesis 
when compared to chow-fed conditions (Supporting 
Fig. S3A,B). Interestingly, we found that 10 weeks 
of high-carbohydrate feeding was accompanied by a 
modest increase in AMPK Thr172 phosphorylation 
in the liver in both WT and HMGCR KI mice, 
suggesting increased AMPK activity (Supporting 
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Fig. S3C). This appeared to be due to increased 
AMPK protein abundance as measured by western 
blot of the AMPK α subunit (Supporting Fig. S3C-
E). These data suggest that a high-carbohydrate diet 
may further exacerbate the phenotype difference 
between WT and HMGCR KI mice as the increased 
AMPK activity under these conditions is unable to 
effectively inhibit HMGCR activity and cholesterol 
synthesis in KI livers. Consistent with this, HMGCR 
KI mice showed significant increases in hepatic and 
serum total and free cholesterol as well as cholesteryl 
esters, the main cholesterol form stored within the cell 
or exported into the blood stream (Fig. 2D,E). Serum 
concentrations of LDL/VLDL cholesterol were 
increased in HMGCR KI mice (Fig. 2F), whereas 
serum HDL cholesterol levels were comparable 
between genotypes (Supporting Fig. S4A), suggesting 
that the hypercholesterolemia in HMGCR KI mice 
was due to secretion of cholesterol-rich lipoproteins 
rather than differences in cholesterol reuptake.
Fig. 2. Elevated serum and hepatic cholesterol levels in high-carbohydrate-fed HMGCR KI mice. (A) Cholesterol synthesis in WT 
and HMGCR KI hepatocytes in response to AMPK activators A769662 and AICAR. Results are means ± SEM, n = 3 independent 
experiments (each experiment contains at least three replicates; *P < 0.05, when comparing WT versus HMGCR KI; ##P < 0.01, 
###P < 0.001, when comparing between different treatments). Liver and serum samples were collected from (B,C) chow-fed WT and 
HMGCR KI mice or (D,E) high-carbohydrate-fed WT and HMGCR KI mice. Cholesterol levels, including total cholesterol, free 
cholesterol, and cholesteryl ester, were measured. (F) Serum LDL/VLDL cholesterol from high-carbohydrate-fed WT and HMGCR 
KI mice. (B-F) Results are means ± SEM, n = 7-10 per genotype (*P < 0.05, ***P < 0.001, when comparing WT versus HMGCR KI).
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Given that the liver is the main site of cholesterol 
production, we assessed hepatic cholesterol synthesis 
in WT and HMGCR KI mice in vivo. We found that 
HMGCR KI mice exhibited significantly enhanced 
rates of cholesterol synthesis (Fig. 3A,B), whereas 
cholesterol efflux remained comparable between gen-
otypes (Supporting Fig. S4B). Consistent with this, 
cholesterogenic genes downstream of Hmgcr, includ-
ing farnesyl diphosphate synthase (Fdps), squalene 
epoxidase (Sqle), and 7-dehydrocholesterol reductase 
(Dhcr7), were markedly elevated by approximately 
2-fold to 3-fold in HMGCR KI livers compared 
to WT littermates (Fig. 3C) despite the absence of 
changes in the mRNA expression of the upstream 
activator sterol regulatory element binding transcrip-
tion factor 2 (Srebf2) (Supporting Fig. S4C). These 
results indicate that the typical negative feedback from 
elevated cellular cholesterol levels may be disrupted 
in HMGCR KI livers, leading to inappropriately 
activated sterol regulatory element binding protein 2 
(SREBP2) transcriptional activity. Collectively, these 
results show that HMGCR Ser871 phosphorylation 
controls cholesterol synthesis under conditions where 
the flux through the mevalonate pathway is enhanced.
inHiBition oF ampK-HmgCR 
signaling leaDs to liVeR 
steatosis
We measured body weight and fat mass to determine 
whether lipogenic diet-challenged HMGCR KI mice 
displayed any differences in body composition. Body 
weights were similar during the early stages, but after 
10 weeks of high-carbohydrate feeding, HMGCR KI 
mice were modestly but significantly heavier than WT 
mice (Fig. 4A). However, when normalized to initial 
body weight, the incremental body weights were com-
parable between WT and HMGCR KI mice (Fig. 
4B). Epididymal fat mass was increased in HMGCR 
KI mice and remained significantly higher when nor-
malized to body weight (Fig. 4C,D), suggesting that 
the differences in body weight gained were associated 
Fig. 3. Enhanced hepatic cholesterol synthesis in vivo in HMGCR KI mice. (A) Rates of cholesterol synthesis in the liver were 
measured in WT and HMGCR KI mice fed a high-carbohydrate diet for 10 weeks. Mice were injected with 3H2O, and livers and 
plasma were collected 1 hour later. Livers were saponified, sterol-containing lipid was extracted, and the incorporated tracer was 
measured by scintillation counting. (B) In vivo hepatic cholesterol synthesis in livers from high-carbohydrate-fed WT and HMGCR 
KI mice. (C) Quantitative RT-PCR was performed to measure expression of genes for cholesterol synthesis pathway enzymes, 
including Fdps, Sqle, and Dhcr7, from the livers of high-carbohydrate-fed WT and HMGCR KI mice. (B,C) Results are means ± SEM, 
n = 6-8 per genotype (*P < 0.05, when comparing WT versus HMGCR KI). Abbreviations: Dhcr7, 7-dehydrocholesterol reductase; 
Fdps, farnesyl diphosphate synthase; Sqle, squalene epoxidase.
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with an increase in adiposity. We next investigated 
hepatic lipid profile in our high-carbohydrate-fed 
HMGCR KI mice. Although liver weights from WT 
and HMGCR KI mice were comparable (Fig. 5A), 
the liver of HMGCR KI mice showed significantly 
elevated hepatic lipid accumulation as determined by 
Fig. 4. Increased adiposity in high-carbohydrate-fed HMGCR KI mice. WT and HMGCR KI mice were fed a high-carbohydrate 
diet for 10 weeks. (A,B) Absolute and incremental weekly body weights of WT and HMGCR KI mice. (C,D) Absolute and normalized 
epididymal fat mass in WT and HMGCR KI mice. Results are means ± SEM, n = 7-10 per genotype (*P < 0.05, **P < 0.01, when 
comparing WT versus HMGCR KI).
Fig. 5. Increased adiposity and hepatic lipid accumulation in high-carbohydrate-fed HMGCR KI mice. WT and HMGCR KI mice 
were fed a high-carbohydrate diet for 10 weeks. (A) Liver weights of WT and HMGCR KI mice. (B) Oil Red O stain of liver tissue from 
high-carbohydrate-fed WT and HMGCR KI mice. (C,D) Hepatic and serum triglyceride levels in WT and HMGCR KI mice. (E) 
Masson’s trichrome stain of liver tissue from high-carbohydrate-fed WT and HMGCR KI mice. (F) F4/80 immunohistochemistry of 
liver tissue from high-carbohydrate-fed WT and HMGCR KI mice. Relative hepatic Il6, Il1b, and Tnfa mRNA expression determined 
in the liver by quantitative RT-PCR. Results are means ± SEM, n = 6-10 per genotype (*P < 0.05, when comparing WT versus 
HMGCR KI). Abbreviation: Tnfa, tumor necrosis factor alpha.
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Oil Red O staining (Fig. 5B). Consistent with this, 
liver and serum triglyceride contents were signifi-
cantly increased in HMGCR KI mice (Fig. 5C,D). In 
addition, HMGCR KI mice also developed mild liver 
fibrosis when assessed by Masson’s trichrome stain-
ing (Fig. 5E). Furthermore, the liver of HMGCR KI 
mice showed elevated macrophage infiltration and 
hepatic inflammation as determined by F4/80 immu-
nohistochemistry accompanied by enhanced hepatic 
proinflammatory cytokines Il6 mRNA expression, 
with no difference in Il1b and tumor necrosis factor 
α (Fig. 5F). To investigate whether the increased lipid 
levels in HMGCR KI liver were a consequence of an 
increased capacity for de novo triglyceride synthesis, 
we incubated WT and HMGCR KI hepatocytes with 
3H-labeled acetate and measured radioactivity of the 
total triglyceride fraction. We found that HMGCR 
KI hepatocytes showed increased rates of triglyceride 
synthesis and reduced responses to the lipid-lowering 
effect of the AMPK activators A769662 and AICAR 
(Fig. 6A). Nevertheless, both A769662 and AICAR 
reduced triglyceride synthesis in HMGCR KI cells 
compared to the basal level, indicating another 
AMPK regulatory step in the triglyceride synthesis 
pathway besides HMGCR, such as the well-known 
inhibition of acetyl-CoA carboxylase (ACC) activity 
by AMPK. The increased lipid synthesis in HMGCR 
KI cells may have been provided by elevated expres-
sion of lipogenic genes because the mRNA expression 
of key enzymes in lipid synthesis, such as ACC-alpha 
(Acaca), ACC-beta (Acacb), and fatty acid synthase 
(Fasn), was significantly up-regulated without signif-
icant changes (albeit a trend) in the expression of the 
upstream transcriptional regulator Srebf1 (Fig. 6B,C). 
These results indicate that the increased intracellular 
cholesterol levels in HMGCR KI mice lead to a con-






The storage and accumulation of excessive lipid in 
insulin-responsive tissues, particularly in the liver, is 
strongly linked to impaired glucose homeostasis and 
the development of insulin resistance.(29) We first 
aimed to test the effect of the HMGCR Ser871Ala 
mutation on the overall regulation of glucose homeo-
stasis. Fed and fasted blood glucose levels were indis-
tinguishable between chow-fed WT and HMGCR 
KI mice (Supporting Fig. S5A). In contrast, high-car-
bohydrate-fed HMGCR KI mice were hyperglycemic 
in the fasting state compared to WT mice (Fig. 7A). 
In line with the higher fasting blood glucose levels, 
whole-body glucose clearance and insulin respon-
siveness as evaluated by glucose and insulin toler-
ance tests, respectively, were significantly impaired in 
HMGCR KI mice (Fig. 7B,C). These impairments 
in glucose tolerance and insulin sensitivity were not 
observed between the two genotypes when fed a 
standard chow diet (Supporting Fig. S5B,C).
Studies have shown that excess plasma mem-
brane cholesterol in skeletal muscle may lead to 
impaired glucose uptake and represent an early 
Fig. 6. Enhanced capacity for de novo triglyceride synthesis in HMGCR KI liver. (A) Triglyceride synthesis in WT and HMGCR KI 
primary hepatocytes in response to AMPK activators A769662 and AICAR. Results are means ± SEM, n = 3 independent experiments 
(each experiment contains at least three replicates; *P < 0.05, when comparing WT versus HMGCR KI). (B,C) mRNA expression of 
lipogenic genes, including Srebf1, Fasn, Acaca, and Acacb, from livers of high-carbohydrate-fed WT and HMGCR KI mice. Results are 
means ± SEM, n = 7-10 per genotype (*P < 0.05, when comparing WT versus HMGCR KI).
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event in the development of skeletal muscle insulin 
resistance.(30,31) To determine whether inhibition of 
AMPK-HMGCR signaling contributes to impaired 
skeletal muscle glucose homeostasis, we measured 
insulin signaling and ex vivo glucose uptake in mus-
cle from WT and HMGCR KI mice. No differences 
were evident in 2-deoxy-D-glucose uptake into WT 
versus HMGCR KI soleus and EDL muscle under 
basal conditions or in response to insulin (Fig. 7D). In 
line with this, no differences in Akt phosphorylation 
were noted in muscle from WT and HMGCR KI 
mice as assessed by immunoblot analysis using anti-
bodies specific for the Akt Ser473 phosphorylation 
site (Fig. 7E), suggesting that altered muscle insulin 
signaling is unlikely to contribute to the impaired glu-
cose homeostasis in HMGCR KI mice. In contrast, 
hepatic Akt phosphorylation was slightly but signifi-
cantly reduced in HMGCR KI mice (Fig. 7F), sug-
gesting that the elevated fasting glucose levels were a 
consequence of impaired hepatic glucose homeostasis. 
We investigated this possibility further in hyperinsu-
linemic-euglycemic clamp experiments. In the basal 
state, HMGCR KI mice exhibited enhanced fasted (6 
hours) blood glucose with comparable glucose levels 
in the clamped state (Fig. 8A; Supporting Fig. S6A). 
The glucose infusion rate (GIR) (Fig. 8B; Supporting 
Fig. S6B) and the glucose disappearance rate (Fig. 
8C), which primarily reflects skeletal muscle glucose 
disposal, were similar between the genotypes. In addi-
tion, there were no differences in Akt phosphoryla-
tion in white adipose tissue or serum NEFA levels 
(Supporting Fig. S6C,D). These results suggest that 
insulin sensitivity in muscle and white adipose tissue 
was not affected. However, HGP was significantly 
higher in HMGCR KI mice in the clamped state 
(Fig. 8D), and the percentage suppression of HGP by 
insulin during the clamp was reduced in HMGCR 
KI compared to WT mice (Fig. 8E). In support of 
Fig. 7. Impaired glucose homeostasis in high-carbohydrate-fed HMGCR KI mice. WT and HMGCR KI mice were fed a high-
carbohydrate diet for 10 weeks. (A) Ad libitum fed and overnight-fasted blood glucose levels from WT and HMGCR KI mice. (B) WT 
and HMGCR KI mice were fasted for 6 hours and injected intraperitoneally with 1 mg/g of glucose. Blood glucose was measured, and 
the area under the curve was calculated. (C) WT and HMGCR KI mice were fasted for 4 hours and injected intraperitoneally with 0.5 
mU/g of insulin; blood glucose was measured, and the area under the curve was calculated. (D) Soleus and EDL muscles were isolated 
from WT and HMGCR KI mice, and 2-deoxy-D-glucose uptake was assessed under basal conditions and in response to insulin. 
(E,F) Liver and muscle from high-carbohydrate-fed WT and HMGCR KI mice were isolated and processed for immunoblotting 
using antibodies specific for phosphorylated Akt (Ser473) and actin. Results are means ± SEM; (A-C,E,F) n = 7-10 per genotype, 
(D) n = 5-6 per genotype (*P < 0.05, when comparing WT versus HMGCR KI). Abbreviations: 2DG, 2-deoxy-D-glucose; pAkt, 
phosphorylated Akt.
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this, the transcript expression of the gluconeogenic 
genes glucose 6-phosphatase (G6pc) and phosphoe-
nolpyruvate carboxykinase 1 (Pck1) was significantly 
higher in the HMGCR KI livers at the completion 
of the clamp, which is entirely consistent with a lack 
of suppression of HGP (Fig. 8F). Taken together, 
these results indicate that HMGCR KI mice have 
increased liver lipid deposition, liver insulin resis-
tance, and enhanced HGP, contributing to impaired 
whole-body glucose homeostasis.
Discussion
Although HMGCR was the second AMPK sub-
strate identified more than 40 years ago and is univer-
sally cited as an example of AMPK’s role in regulating 
cholesterol metabolism, evidence supporting this has 
largely been confined to in vitro cell-based experi-
ments.(19) Importantly, in vitro evidence that both 
WT and HMGCR Ser871Ala mutant were equally 
regulated by sterol feedback control indicated that 
the phosphorylation of HMGCR is only important 
during metabolic stress, a common theme in AMPK 
signaling. However, an important unanswered ques-
tion is what role AMPK-HMGCR signaling plays 
under normal homeostatic conditions and in the pres-
ence of nutrient-saturated diets that are common in 
many countries and known to be an important con-
tributing factor to the development of obesity and 
type 2 diabetes. To answer this question, we gener-
ated a mouse model with a KI point mutation that 
results in the substitution of HMGCR Ser871 with 
Ala (HMGCR KI) in order to directly assess the 
importance of AMPK phosphorylation of HMGCR 
without altering AMPK’s numerous other functions, 
which could affect liver metabolism, including the 
inhibition of SREBP(32) or ACC.(24) Mice with the 
HMGCR Ser871Ala mutation were viable, bred nor-
mally according to Mendelian ratios, and had similar 
tissue weights as WT littermate controls. A detailed 
histologic examination of various organs in these mice 
Fig. 8. Increased HGP in high-carbohydrate-fed HMGCR KI mice. (A-F) Hyperinsulinemic-euglycemic clamp studies in high-
carbohydrate-fed WT and HMGCR KI mice. (A) Blood glucose levels, (B) glucose infusion rate, and (C) whole-body glucose 
disappearance rate during the clamp. (D,E) Hepatic glucose output during basal and insulin-stimulated conditions and expressed as 
percent suppression. (F) Quantitative RT-PCR was performed to measure expression of genes for gluconeogenic genes, including Pck1 
and G6pc, from the livers of high-carbohydrate-fed WT and HMGCR KI mice after the clamp. Results are means ± SEM, n = 4 per 
genotype (**P < 0.01, ***P < 0.001, when comparing WT versus HMGCR KI). Abbreviations: G6pc, glucose 6-phosphatase; Pck1, 
phosphoenolpyruvate carboxykinase 1.
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revealed no morphologic defects or pathologies (data 
not shown). We confirmed that the Ser871Ala muta-
tion rendered HMGCR insensitive to inhibition by 
AMPK activators in primary hepatocytes.
There were no metabolic or phenotypic differ-
ences between WT and HMGCR Ser871Ala KI 
mice under chow-fed conditions apart from a mod-
est increase in total serum cholesterol. However, 
metabolic differences emerged when the mice 
were challenged with metabolic stress induced by a 
high-carbohydrate diet and increased flux through 
the mevalonate pathway, leading to increases in liver 
and serum cholesterol levels due to enhanced rates 
of cholesterol synthesis. Importantly, these increased 
rates of cholesterol synthesis also led to elevations in 
liver and serum triglycerides and early signs of liver 
fibrosis and inflammation. Although the precise cause 
of nonalcoholic fatty liver disease (NAFLD) remains 
unclear, the incidence of NAFLD under conditions of 
normal caloric intake seems to be specifically linked 
to disruptions in liver cholesterol metabolism.(33-37) In 
support of this, studies in humans and animal mod-
els have shown that fatty liver can be established by 
a hypercholesterolemic diet containing normal calorie 
levels.(33-37) This suggests that increased levels of cho-
lesterol may enhance lipid accumulation in the liver. 
Mechanistically, cholesterol overload is associated 
with increased accumulation of oxysterols, cholesterol 
metabolites that act as agonists for liver X receptor 
α (LXRα), which is up-regulated in patients with 
NAFLD.(38) LXRα in turn activates the transcription 
factor SREBP1c and results in increased expression 
of genes involved in fatty acid synthesis.(38) This was 
supported by studies showing that LXRα antagonism 
attenuates high-fat diet-induced NAFLD in mice.(39) 
It is therefore possible that the increased cholesterol 
levels in HMGCR KI liver may have led to an over-
expression of lipogenic genes by a similar mechanism, 
resulting in the liver steatosis and fibrosis observed in 
HMGCR KI mice. Although we convincingly show 
that AMPK activation is able to inhibit HMGCR 
activity and decrease cholesterol synthesis in vivo, 
our study cannot exclude the possibility that other 
mevalonate pathway products, including dolichol, ger-
anylpyrophosphate, and farnesylpyrophosphate, may 
also contribute to the overall metabolic phenotypes of 
HMGCR KI mice.
The liver releases lipids in the form of lipoproteins 
that contain mostly triglyceride and to a lesser extent 
cholesterol, cholesteryl ester, and phospholipids.(40) 
The mobilization of triglyceride and cholesteryl ester 
from the intracellular lipid droplet and packaging into 
lipoproteins requires a series of de-esterification and 
re-esterification steps catalyzed by cholesteryl ester-
ases, lipases, and triglyceride hydrolases, which all 
contain a consensus neutral lipid binding domain.(40) 
In agreement with this, it has been shown that 
increased cholesteryl ester in the liver might compete 
with triglycerides for hydrolysis and lead to decreased 
triglyceride secretion, thereby increasing lipid storage 
in the liver.(41) However, this mechanism is unlikely 
to be the cause of increased hepatic lipid content in 
HMGCR KI mice because serum triglyceride con-
centrations were increased, indicating that there was 
no defect in lipid secretion from KI livers. Given the 
capacity of autophagy to mediate lipid degradation, it 
has been suggested that impaired hepatic autophagy 
plays a role in the development of liver steatosis.(42,43) 
In addition, statin-mediated inhibition of HMGCR 
has been shown to markedly induce autophagic flux 
by suppressing the mevalonate pathway.(44) Thus, 
impairment in autophagy due to a gain-of-function 
of HMGCR could be a potential mechanism that is 
directly or indirectly responsible for the hepatic ste-
atosis seen in HMGCR KI mice. Furthermore, in 
addition to increased lipogenic and gluconeogenic 
genes, HMGCR KI mice exhibited enhanced mac-
rophage infiltration and elevated proinflammatory 
cytokine Il6 expression. In NAFLD subjects, both 
nuclear factor kappa B and mitogen-activated protein 
kinase pathways were found to be enhanced and have 
a direct correlation with hepatic inflammation and 
fibrosis.(45,46) Thus, it is possible that these pathways 
may also indirectly mediate some of the phenotypes 
besides the up-regulation of cholesterol synthesis in 
HMGCR KI mice
Recently, Woods et al.(47) reported that mice 
expressing a constitutively active form of AMPK 
(γ1-Asp316Ala) in the liver were protected from 
developing hepatic steatosis on a high-fructose diet. 
These mice had essentially the reciprocal phenotype 
to the HMGCR KI mice that develop steatosis on a 
high-carbohydrate diet. However, there are some sub-
tle differences. In the liver-specific γ1-Asp316Ala mice 
fed a high-fructose diet, accumulation of hepatic tri-
glyceride is blocked and glucose output from the liver 
is inhibited but there is no change in Fasn or Acaca 
expression. Furthermore, despite the increased AMPK 
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activity in the γ1-Asp316Ala mice, there was no sup-
pression of cholesterol synthesis. Thus, these results 
suggest that activated AMPK in the γ1-Asp316Ala 
mice can effectively shut down lipid accumulation by 
acutely phosphorylating ACC1/2, without the require-
ment of regulating cholesterol synthesis. In contrast, 
in the HMGCR KI mice, the increase in hepatic tri-
glyceride is accompanied by increased glucose output 
from the liver as well as increased mRNA expression 
of the SREBP1c gene targets Fasn, Acaca, and Acacb. 
The increased synthesis of cholesterol in the HMGCR 
KI mice seems to drive de novo fatty acid synthesis and 
leads to hepatic steatosis, despite AMPK signaling to 
ACC1/2 remaining intact. Together, these data imply 
that acute AMPK signaling to downstream substrates 
is responsible for the suppression of triglyceride synthe-
sis, yet blocking AMPK signaling to HMGCR alone 
is sufficient to enhance hepatic triglyceride synthesis.
Overall, we show that AMPK-HMGCR signaling 
is important in the regulation of cholesterol biosyn-
thesis in vivo. Inhibition of this control mechanism 
under conditions of metabolic stress, such as high-car-
bohydrate feeding, not only leads to hypercholesterol-
emia but unexpectedly also results in hepatic steatosis 
and fibrosis, suggesting that direct therapeutic target-
ing of the AMPK-HMGCR signaling pathway may 
be an attractive strategy for preventing the onset and 
progression of NAFLD.
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